Poor penetration of therapeutic drugs
into tumors is a major challenge
in anticancer therapy, especially in solid tumors, leading to reduced
therapeutic efficacy in vivo. In the study, we used a new tumor-penetrating
peptide, CRGDK, to conjugate onto the surface of doxorubicin encapsulated
nanoscale micelles. The CRGDK peptide triggered specific binding to
neuropilin-1, leading to enhanced cellular uptake and cytotoxicity
in vitro and highly accumulation and penetration in the tumors in
vivo.